# A Multicenter, Randomized, Evaluator-Blind, No-Treatment Controlled Study of YVOIRE Y-Solution 720: A Volumizing Hyaluronic Acid Filler for Midface Volume Deficit

## TL;DR

A study evaluated the effectiveness and safety of YVOIRE Y-Solution 720, a hyaluronic acid filler, for improving midface volume in Asian participants.

## Contribution

This is the first multicenter, randomized, evaluator-blind study of YYS720 for midface volume augmentation in Asian populations.

## Key findings

- 82.0% of YYS720-treated participants showed significant improvement in midface volume at Week 26.
- Safety profile of YYS720 was favorable with mild and transient side effects.
- Improvement in midface volume was maintained up to 52 weeks post-treatment.

## Abstract

Midface volume deficiency is a common aesthetic concern that can be addressed with dermal fillers. YVOIRE Y-Solution 720 (YYS720) is a hyaluronic acid (HA)-based filler designed for midface augmentation. This study aimed to evaluate the effectiveness and safety of YYS720 in improving midface volume.

Asian participants with mild to severe midface volume loss were randomly assigned to receive either YYS720 injection (n = 173) or no treatment (control, n = 65). Midface volume was evaluated at 4, 14, and 26 weeks using Midface Volume Deficit Severity Rating Scale for Asian Faces (MFVDA-SRS) for both YYS720 and control groups. Additionally, for YYS720, midface volume was evaluated 52 weeks after the last injection.

At Week 26, the proportion of participants with ≥ 1-grade reduction on the MFVDA-SRS score was 82.0% (137/167 participants) for YYS720 and 5.1% (3/59 participants) for control with difference (95% confidence interval, CI) between the groups of 77.0% (66.8, 84.0), demonstrating the statistically significant improvement of YYS7720 in midface augmentation. At Week 52, the proportion of participants with ≥1-grade reduction on the MFVDA-SRS score was 76.2% for YYS720 group. Global Aesthetic Improvement Scale (GAIS) responder rates by participants were consistently high in YYS720 group across all time points up to Week 26. No specific safety concern was detected. Common treatment site responses included swelling, tenderness, and pain, which were generally mild and transient.

This study supports that YVOIRE Y-Solution 720 is an effective and safe option for midface volume augmentation.

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.

The online version contains supplementary material available at 10.1007/s00266-025-05246-4.